Welcome to our dedicated page for Pmv Pharmaceuticals SEC filings (Ticker: PMVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a clinical-stage biotech is hard. PMV Pharmaceuticals’ SEC filings weave together p53 science, cash-burn math, and milestone disclosures that span hundreds of pages. If you’ve ever asked, “How do I find PMV Pharmaceuticals’ quarterly earnings report 10-Q filing?” or needed “PMV Pharmaceuticals insider trading Form 4 transactions” before the market reacts, you know the challenge.
Stock Titan solves it. Our AI-powered summaries turn dense 10-Ks into clear takeaways—R&D spend, cash runway, and risk factors—so “PMV Pharmaceuticals annual report 10-K simplified” is more than a promise. Real-time EDGAR feeds push “PMV Pharmaceuticals Form 4 insider transactions real-time” to your dashboard within seconds, letting you monitor executive stock moves the moment they’re filed. Need context on a sudden press release? Click the linked 8-K; our engine delivers “PMV Pharmaceuticals 8-K material events explained” with plain-English highlights.
Every filing type is covered: 10-Q earnings reports for trial-funding updates, 8-K notices for dose-escalation data, Schedule 13G for institutional positions, and the proxy statement for “PMV Pharmaceuticals proxy statement executive compensation” details. Use cases include comparing quarter-over-quarter burn, tracking pipeline progress through clinical milestones, and spotting “PMV Pharmaceuticals executive stock transactions Form 4” that precede key readouts. Whether you search for “understanding PMV Pharmaceuticals SEC documents with AI” or “PMV Pharmaceuticals earnings report filing analysis,” Stock Titan delivers concise answers, real-time alerts, and downloadable originals—so you spend time analyzing opportunities, not hunting for documents.
PMV Pharmaceuticals, Inc. (PMVP) filed a Form 4 disclosing that General Counsel & COO Robert Ticktin sold 23,151 common shares on 1 July 2025 at an average price of $1.0648 per share.
The filing states the shares were withheld for tax obligations arising from the vesting of restricted stock units (RSUs). Following the transaction, Ticktin retains 98,695 shares of PMVP, which include 15,528 shares purchased under the company’s Employee Stock Purchase Plan on 15 May 2025. No derivative security transactions were reported.
The sale represents a disposition of approximately 19% of his prior directly held shares; however, because the purpose is tax-related rather than discretionary, the market signal is typically viewed as neutral.
Form 4 highlights (AEHR – 07/02/2025): President & CEO Gayn Erickson reported two equity awards and one tax-related share withholding.
- Equity awards: 13,528 and 63,847 restricted stock units (RSUs) were granted at $0 cost, totalling 77,375 new shares. 25 % of one grant vests immediately; the balance vests quarterly over three years. The second grant vests in equal sixteenth-monthly installments.
- Post-transaction ownership: Direct holdings rise to 280,570 shares; an additional 291,088 shares are held indirectly via trust, bringing total beneficial ownership to roughly 571,658 shares.
- Tax withholding: 1,822 shares (code F) were withheld at $15.13 solely to cover taxes on vesting; this is not an open-market sale and represents <0.3 % of Erickson’s total holdings.
The sizeable RSU grants expand the CEO’s stake and link future compensation to share-price performance, signalling alignment with shareholders. No discretionary sales were made, and the only disposition was administrative, suggesting a neutral-to-slightly-positive governance signal without immediate earnings or cash-flow impact.
PMV Pharmaceuticals (PMVP) – Form 4 insider transaction
Chief Financial Officer Michael Carulli disclosed the sale of 28,249 common shares on 01 July 2025 at a weighted-average price of $1.0647 per share. According to the filing, the disposition was made solely to satisfy tax-withholding obligations triggered by the vesting of restricted stock units (RSUs). After the transaction, the executive continues to beneficially own 60,146 shares of PMVP common stock, and no derivative security activity was reported. The sale represents a cash value of roughly $30,000 and leaves the CFO with a meaningful equity stake, limiting the signaling impact for investors.
PMV Pharmaceuticals, Inc. (PMVP) – Form 4 insider transaction
President & CEO David Henry Mack reported a sale of 58,411 common shares on 07/01/2025 at an average price of $1.0645 per share. The sale was executed under Rule S (open-market or private sale) and, according to the filing, was undertaken solely to cover tax obligations arising from the vesting of restricted stock units (Footnote 1).
After the transaction, Mack continues to own 536,133 shares directly. He also has indirect interests of 165,307 shares (Stinson 2021 Irrevocable Trust), 147,915 shares (Mack-Mulligan Revocable Trust) and 56,978 shares (Mack/Mulligan 2020 Irrevocable Descendants’ Trust), bringing his total reported beneficial position to 906,333 shares. No derivative securities were bought or sold, and there were no new options, warrants, or RSU transactions reported.
The sale represents roughly 10.9 % of Mack’s direct holdings and about 6.4 % of his total reported beneficial ownership. Because the disposition was for tax-withholding purposes, it does not necessarily signal a change in sentiment; nevertheless, investors often monitor any CEO share sales for potential insight into insider views of future prospects.
FAQ
What is the current stock price of Pmv Pharmaceuticals (PMVP)?
What is the market cap of Pmv Pharmaceuticals (PMVP)?
What is the primary focus of PMV Pharmaceuticals?
How does PMV Pharmaceuticals approach cancer treatment?
What differentiates PMV Pharmaceuticals from other biotech firms?
How does the company generate value in the oncology market?
What stage of development are PMV Pharmaceuticals' therapies in?
What are the key technological approaches used by PMV Pharmaceuticals?
How does PMV manage challenges in drug development?
How is PMV Pharmaceuticals positioned within the competitive oncology landscape?
